Survey covered 25 U.S.-based healthcare providers in 14 states, representing diverse practice settings, conducted in mid‑to‑late May 2026.
Current market penetration: oral GLP‑1 therapies represent 10 % or less of new weekly obesity prescriptions.
Providers anticipate oral GLP‑1s will broaden the total addressable patient population rather than replace injectable options, projecting oral share will remain below 50 % of the overall treatment mix over the next few years.
Primary adoption barriers identified are cost and insurance coverage; tolerability concerns were not highlighted.
Competitive perception: oral Wegovy (Novo Nordisk) viewed as more effective, while Foundayo is favored for ease of use because it eliminates fasting and food‑timing requirements.
Prescribing intent is roughly balanced at 52 % for Foundayo versus 48 % for Wegovy.
Preference metrics: 68 % of surveyed providers prefer Foundayo for ease of use; 60 % consider tolerability comparable between the two products.
Marketing activity: Foundayo began television advertising during the NBA finals three weeks earlier than originally planned.
